THE WOODLANDS, April, 9 2015 – Texas–(BUSINESS WIRE)– Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has completed its previously announced rights offering. Opexa raised $13,804,140 in gross proceeds, before expenses, through subscriptions for 25,098,437 units, including the exercise of over-subscription privileges. Each unit is composed of one share of common stock and a warrant to purchase one additional share of common stock. Net proceeds, after deduction of fees and expenses, including dealer-manager fees, are expected to be approximately $12 million.
Maxim group acted as a lead dealer-manager for Opexa Therapeutics $13.8 million rights offering.